Clinical trials: Cancer Esophagus
Esophageal Cancer
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066716
- Testing
- carboplatin, celecoxib, paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Weill Medical College of Cornell University
Esophageal Cancer
Evaluation of the Effectiveness of the Combined Psychological Resilience and Self-efficacy Intervention for Improving Resilience and Self-efficacy and Reducing Anxiety and Depression of Oesophageal Cancer Surgery Patients
The goal of this clinical trial is to evaluate the effectiveness of the combined psychological resilience and self-efficacy intervention in oesophageal cancer surgery patients.
- Trial name
- NCT06484842
- Testing
- The combined psychological resilience and self-efficacy intervention, The mindfulness intervention
- Volunteers
- 123 people
- Sponsor
- Anhui Medical University
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Esophageal Cancer
Balloon Dilation to Permit Complete Endoscopic Ultrasound Staging in Esophageal Cancer
Despite improvement in treatment-related morbidity and mortality, esophageal cancer is still one of the most lethal malignancies. Accurate staging is essential to establish prognosis and for patient management.
- Trial name
- CT0046 (NCT01950442)
- Testing
- Balloon dilation
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Breast Cancer, Esophageal Cancer
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT01172028
- Testing
- Taxotere (Docetaxel), Alimta (Pemetrexed)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Arizona
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
In this trial, FLOT will be evaluated as therapy option for elderly patients (>65 years) with advanced gastric cancer in comparison to the well established FLO scheme.
- Trial name
- NCT00737373
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- Krankenhaus Nordwest
Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma
The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy.
- Trial name
- NCT07596654
- Where
- China
- Volunteers
- 4 people
- Sponsor
- yi shen
Esophageal Cancer, Liver Cirrhosis
Esophagectomy in Patients With Liver Cirrhosis
Retrospective and confounder adjusted comparison of perioperative and longterm outcomes of patients requiring an esophagectomy for esophageal cancer with and without concomitant liver cirrhosis.
- Trial name
- NCT04809870
- Testing
- surgery
- Where
- Germany
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Esophageal Cancer
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
1. Research methods Constructed the "Manual for Graded Management of Postoperative Symptoms of Esophageal Cancer" and developed continuous care Procedures. 2.
- Trial name
- NCT07187154
- Testing
- Smart Symptom Management Program
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease, Barrett Esophagus
The Johns Hopkins Heartburn Center Registry
A multi-center, multi-year registry of patients with gastroesophageal reflux disease (GERD) undergoing diagnostic evaluation and/or treatment of GERD and associated diseases and complications.
- Conditions
- Gastroesophageal Reflux Disease, Barrett Esophagus, Laryngopharyngeal Reflux, Esophagitis
- Trial name
- NCT03853772
- Where
- 9 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Johns Hopkins University
Advanced Solid Tumors, Gastric Cancer
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT02318329
- Testing
- FPA144
- Where
- 26 sites in United States, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Five Prime Therapeutics, Inc.
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
CNS Brain Metastasis, Head and Neck Cancer
Pilot Study of 18F-FLT PET
Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging.
- Conditions
- CNS Brain Metastasis, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00585741
- Testing
- Imaging with 18F-FLT PET
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Esophageal Cancer
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of a modified neoadjuvant immunotherapy plus chemotherapy (one cycle of Tislelizumab monotherapy followed by four cycles of…
- Trial name
- TRACE (NCT06469060)
- Testing
- neoadjuvant anti-PD-1 with DOC chemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai Chest Hospital
Bladder Cancer, Cervical Cancer
Acceptability of Less Harmful Alternatives to Cigarettes
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00957424
- Testing
- telephone-based intervention, nicotine replacement therapy, informational intervention
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Roswell Park Cancer Institute
Barrett's Esophagus With Dysplasia
Ursodeoxycholic Acid in Barrett's Endotherapy
Barrett's esophagus (BE) is a condition in which the normal lining of the esophagus is replaced by abnormal tissue that can increase the risk of esophageal cancer.
- Trial name
- NCT07756710
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
This is a Phase I, open-label, dual-cohort clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of intratumoral injection of recombinant human endostatin adenovirus in combination with a PD-1…
- Trial name
- NCT07154108
- Testing
- recombinant human endostatin adenovirus, PD-1 Inhibitor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.